ArticleScientific reports2018
Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 6 syntheses or guidelines pooled it, 157 citations in OpenAlex.
- Cerebrospinal Fluid Biomarkers of NLRP3 Pathway, Immune Dysregulation, and Neurodegeneration in Parkinson's Disease: A Meta-Analysis.Movement disorders : official journal of the Movement Disorder Society · 2026Pooled it
- The Cognitive Profile of Atypical Parkinsonism: A Meta-Analysis.Neuropsychology review · 2023Pooled it
- Inflammatory markers and depression in Parkinson's disease: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Pooled it
- Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis.Journal of neurology · 2021Pooled it
- Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson's Disease: A Meta-Analysis.Behavioural neurology · 2021Pooled it
- C-Reactive Protein and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis.Frontiers in neurology · 2019Pooled it
- Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.Nature medicine · 2021Trial
- Immune system modifications in atypical parkinsonism related to autoimmunity - a case control study.Neurodegenerative disease management · 2026Article
- Distinct plasma inflammatory signatures reflect disease severity and progression in progressive supranuclear palsy: a prospective cohort study.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- A preliminary analysis of the inflammatory protein landscape in the CSF of mid- to late-stage Parkinson's disease: associations with motor severity and subtypes.BMC neurology · 2026Article
- Characteristics and mechanisms of cognitive impairment in Parkinson disease.Nature reviews. Neurology · 2026Review
- Tracing neuroinflammation in neurodegeneration: insights from a scoping review on biofluid biomarkers.Brain communications · 2026Review
- Peripheral and CSF protein quantification in Parkinson's disease and multiple system atrophy-the nucleic acid-linked immuno-sandwich assay.Brain communications · 2026Article
- Antimicrobial Peptides as Cross-Seeding Modulators at the Neurodegenerative-Infectious Interface.Research (Washington, D.C.) · 2026Review
- Review
- Retrospective analysis of neurofilament-light chain in patients with inflammatory bowel disease - A pilot study.PloS one · 2026Article
- Emerging biomarkers for Parkinson's disease in biological fluids.Frontiers in aging neuroscience · 2026Review
- Peripheral and central inflammation in progressive supranuclear palsy syndrome: an immunological and imaging neuroinflammation study.Frontiers in immunology · 2026Article
- Inflammatory and Neurotrophic Factors and Their Connection to Quality of Life in Progressive Supranuclear Palsy-Single-Center Study.International journal of molecular sciences · 2025Article
- Soluble immune factor profiles in blood and CSF associated with LRRK2 mutations and Parkinson's disease.NPJ Parkinson's disease · 2025Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation has been implicated in the pathogenesis of Parkinson's disease (PD). We here investigate levels of inflammatory biomarkers in cerebrospinal fluid (CSF) in PD and atypical parkinsonian disorders (APD) compared with neurologically healthy controls. We included 131 patients with PD and 27 PD with dementia (PDD), 24 with multiple system atrophy (MSA), 14 with progressive supranuclear palsy (PSP) and 50 controls, all part of the Swedish BioFINDER study. CSF was analyzed for CRP, SAA, IL-6, IL-8, YKL-40 and MCP-1 (CCL2) as well as α-synuclein (α-syn), tau, tau phosphorylated at Thr181 (P-tau), Aβ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.